Evidence map›Paper›PMID 41702822›Full record

ArticleJournal of clinical lipidology2026

The impact of genetic testing on physician practice in specialized cardiovascular clinics.

Arsalan Hamid, Tyler Sewell, Sucheta Bhatt, Scott Spencer, Damon Hostin, Ginger A Metcalf, Richard A Gibbs, Vijay Nambi, Layla A Abushamat, Christie M Ballantyne

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical lipidology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arsalan HamidDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne).
Tyler SewellSchool of Medicine, Baylor College of Medicine, Houston, TX, USA (Sewell).
Sucheta BhattIllumina Inc, San Diego, CA, USA (Drs Bhatt and Spencer, and Hostin).
Scott SpencerIllumina Inc, San Diego, CA, USA (Drs Bhatt and Spencer, and Hostin).
Damon HostinIllumina Inc, San Diego, CA, USA (Drs Bhatt and Spencer, and Hostin).
Ginger A MetcalfHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA (Metcalf and Dr Gibbs).
Richard A GibbsHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA (Metcalf and Dr Gibbs); Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA (Drs Gibbs and Ballantyne).
Vijay NambiDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne); Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA (Dr Nambi).
Layla A AbushamatDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne).
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne); Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA (Drs Gibbs and Ballantyne). Electronic address: cmb@bcm.edu.

Funding

Mechanisms and consequences of erythritol and erythronate excess in cardiometabolic diseaseK23DK140641 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Layla A Abushamat · 2024 to 2026
$583k
NIDDK NIH HHS K23 DK140641
6 · The paper itself

Abstract

backgroundAlthough familial hypercholesterolemia (FH) is a US Centers for Disease Control and Prevention tier 1 condition for genetic testing, the impact of testing on clinical outcomes is unclear.

objectiveWe aimed to assess whether genetic testing alters lipid management in HeartCare participants.

methodsFor participants with pathogenic/likely pathogenic variants for FH observed at Baylor College of Medicine cardiology clinics, data on laboratory values, medication prescriptions, and diagnoses were collected and compared before and after genetic testing.

resultsIn the 20 participants with APOB/LDLR variants and complete data, low-density lipoprotein cholesterol (LDL-C) was numerically lower but not significantly different before vs after genetic testing (103 vs 79.5 mg/dL). Sixteen (80%) participants were from the lipid clinic; the majority had a preexisting FH diagnosis. LDL-C levels were numerically lower, and more patients received proprotein convertase subtilisin/kexin type 9 inhibitor prescriptions after genetic testing; however, the difference was not statistically significant.

conclusionsThe majority of patients with FH achieved LDL-C <100 mg/dL after genetic testing; however, most patients with APOB/LDLR variants were from the lipid clinic and had been diagnosed with FH by clinical criteria.

Indexed as

Cardiovascular DiseasesGenetic TestingHyperlipoproteinemia Type IIPractice Patterns, Physicians'AdultApolipoproteins BCholesterol, LDLFemaleHumansMaleMiddle AgedReceptors, LDLApolipoproteins BCholesterol, LDLReceptors, LDLClinical practiceFamilial hypercholesterolemiaGeneticsLDL cholesterolLipids

Identifiers

PMID41702822
PMCPMC13012867

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.